Kuros Biosciences AG
SIX:KURN

Watchlist Manager
Kuros Biosciences AG Logo
Kuros Biosciences AG
SIX:KURN
Watchlist
Price: 21 CHF -4.46% Market Closed
Market Cap: 789m CHF
Have any thoughts about
Kuros Biosciences AG?
Write Note

Kuros Biosciences AG
Total Other Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Kuros Biosciences AG
Total Other Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Other Income CAGR 3Y CAGR 5Y CAGR 10Y
Kuros Biosciences AG
SIX:KURN
Total Other Income
CHf163k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Total Other Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Total Other Income
$103.9m
CAGR 3-Years
159%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Total Other Income
CHf2m
CAGR 3-Years
50%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Idorsia Ltd
SIX:IDIA
Total Other Income
-CHf16.5m
CAGR 3-Years
-26%
CAGR 5-Years
-47%
CAGR 10-Years
N/A
S
Santhera Pharmaceuticals Holding AG
SIX:SANN
Total Other Income
CHf0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Kuros Biosciences AG
Glance View

Market Cap
795.2m CHF
Industry
Biotechnology

Kuros Biosciences Ltd. engages in the discovery, development and prospective commercialization of a new class of biopharmaceutical products that are intended for use in the treatment and prevention of chronic diseases. The company is headquartered in Schlieren, Zuerich and currently employs 58 full-time employees. The company went IPO on 2002-10-29. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The firm has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The firm has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.

KURN Intrinsic Value
3.38 CHF
Overvaluation 84%
Intrinsic Value
Price

See Also

What is Kuros Biosciences AG's Total Other Income?
Total Other Income
163k CHF

Based on the financial report for Dec 31, 2024, Kuros Biosciences AG's Total Other Income amounts to 163k CHF.

Back to Top